Innovative use of industrially produced steel slag powders in asphalt mixture to replace mineral fillers

Using steel slag to partially replace the natural aggregate in asphalt mixture to produce high-performance asphalt mixture has gained significant interest in recent years as a value-added option to recycle steel slag. However, the poor homogeneity of the material properties of steel slag aggregates remains a concern for this recycling approach. In this study, an innovative method of using industrially produced steel slag powder (SSP) to replace the mineral filler in asphalt mixture was proposed to address this concern. Five fillers, including four SSP fillers, obtained by grinding different steel slag aggregates with an industrialized production line, and one conventional limestone powder (LP) filler, were evaluated. The chemical compositions and micro-morphologies of the SSPs were first characterized to evaluate the material homogeneity and gain insights into the advantages of using SSPs as fillers. Then, asphalt mixtures with different fillers were designed and produced, and their moisture stability, rutting resistance, and low-temperature crack resistance, were characterized. It was found that the industrially produced SSPs possessed homogeneous properties, and improved the compatibility between filler particles and asphalt binder. Besides, the asphalt mixtures with SSP fillers showed better resistance to the moisture damage, permanent deformation, low-temperature crack in terms of fracture energy, than the asphalt mixture with LP filler. Therefore, it was concluded that using SSPs as a replacement of mineral fillers in asphalt mixture provided a reliable and value-added solution to recycle steel slag

FGFC1 Exhibits Anti-Cancer Activity via Inhibiting NF-κB Signaling Pathway in <i>EGFR</i>-Mutant NSCLC Cells

FGFC1, an active compound isolated from the culture of marine fungi Stachybotrys longispora FG216, elicits fibrinolytic, anti-oxidative, and anti-inflammatory activity. We have previously reported that FGFC1 inhibited the proliferation, migration, and invasion of the non-small cell lung cancer (NSCLC) cells in vitro. However, the precise mechanisms of FGFC1 on NSCLC and its anti-cancer activity in vivo remains unclear. Hence, this study was focused to investigate the effects and regulatory mechanisms of FGFC1 on two NSCLC cell lines, EGFR-mutant PC9 (ex19del) and EGFR wild-type H1299. Results suggested that FGFC1 significantly inhibited proliferation, colony formation, as well as triggered G0/G1 arrest and apoptosis of PC9 cells in a dose- and time-dependent manner, but no obvious inhibitory effects were observed in H1299 cells. Subsequently, transcriptome analysis revealed that FGFC1 significantly down-regulated 28 genes related to the NF-κB pathway, including IL-6, TNF-α, and ICAM-1 in the PC9 cells. We further confirmed that FGFC1 decreased the expression of protein p-IKKα/β, p-p65, p-IκB, IL-6, and TNF-α. Moreover, NF-κB inhibitor PDTC could strengthen the effects of FGFC1 on the expression of CDK4, Cyclin D1, cleaved-PARP-1, and cleaved-caspase-3 proteins, suggesting that the NF-κB pathway plays a major role in FGFC1-induced cell cycle arrest and apoptosis. Correspondingly, the nuclear translocation of p-p65 was also suppressed by FGFC1 in PC9 cells. Finally, the intraperitoneal injection of FGFC1 remarkably inhibited PC9 xenograft growth and decreased the expression of Ki-67, p-p65, IL-6, and TNF-α in tumors. Our results indicated that FGFC1 exerted anti-cancer activity in PC9 cells via inhibiting the NF-κB signaling pathway, providing a possibility for FGFC1 to be used as a lead compound for the treatment of NSCLC in the future